Pharmaceuticals, Biotechnology and Life Sciences
Allergan has announced that the latest addition to the Juvederm collection of fillers, Juvederm Volbella XC, is now available to physicians and patients for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as “lipstick lines”, in adults over the age of 21.
Allergan announced that Sweden has received the Marketing Authorisation for BELKYRA (deoxycholic acid) after being granted approval by the Swedish Medical Products Agency (MPA).
The approval of the AC-170 NDA after December 1, 2016 would trigger a milestone payment of $10 million in Nicox shares to ex-Aciex shareholders or $35 million in Nicox shares if approval of the NDA is received before this date.
Nicox S.A. the international ophthalmic R&D company, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for AC-170, its novel, proprietary, cetirizine eye drop formulation, for the treatment of ocular itching associated with allergic conjunctivitis.
Dechra, an international specialist veterinary pharmaceuticals company, has received approval from the U.S. Food and Drug Administration (FDA) for a generic antibiotic.
PureTech gets grant for third U.S. patent for methods of treating infectious and allergic diseases
Allergan’s Vraylartm (cariprazine), a once-daily oral atypical antipsychotic, is now available by prescription in pharmacies throughout the U.S. As Allergan…
On January 28, 2016, the United States Food and Drug Administration (FDA) approved Zepatier (elbasvir and grazoprevir) for the treatment of chronic genotype 1 or 4 hepatitis C virus (HCV) infection in adults.
United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance to Horizon Pharma for U.S. patent application number…
The European Commission has granted to AstraZeneca marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.